Proposed Title X guidance would elevate restorative reproductive medicine — a practice not always based on evidence Published April 28, 2026 6:30AM (EDT) President Donald Trump is seen during a health care affordability event where he announced a deal with pharmaceutical company Regeneron to lower drug prices, in the Oval Office of the White House in Washington, DC, on April 23, 2026. (Photo by Brendan SMIALOWSKI / AFP via Getty Images) In early April, the Centers for Disease Control and Prevention released data indicating fertility rates in the U.S. had hit an all-time low, part of a broader downward trend over the last two decades. Around the same time the report was released, the Trump administration moved closer to a complete overhaul of the Title X family planning program , which provides birth control and other sexual health services to millions of low-income people in the U.S.…